Clinical Trials

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07261683 2025-12-19

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

Phase 2 Recruiting

20 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Ovarian Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03029403 2025-09-19

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

47 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04387227 2025-09-18

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

22 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04575961 2025-05-23

PERCEPTION

33 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Cystadenocarcinoma, Serous

NCT04713514 2024-12-02

TEDOVA

180 enrolled

Ovarian Neoplasms, Recurrence

NCT03596281 2024-10-18

PEMBOV

Phase 1 Completed

47 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Ovarian Neoplasms

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

200 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03126812 2024-05-29

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Phase 1/2 Completed

33 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03732950 2024-04-15

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

5 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05368207 2024-03-13

Pemb-HT

Phase NA Unknown

1 enrolled

Ovarian Neoplasms, Carcinoma, Small Cell

NCT03012620 2024-02-28

AcSé

CNSEndocrineGynecologicHead & NeckLymphoidSarcoma

334 enrolled

Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Lymphoma, Extranodal NK-T-Cell

NCT02766582 2024-02-26

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

29 enrolled 9 charts

Ovarian Neoplasms

NCT02901899 2024-02-20

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

45 enrolled 11 charts

BreastDermatologicGastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05746897 2024-01-26

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Phase 1 Recruiting

38 enrolled

Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04417192 2023-07-06

OLAPem

30 enrolled

BreastGastrointestinalGynecologicThoracic

Ovarian Neoplasms

NCT05431582 2023-06-15

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03410784 2023-03-24

MITO28MaNGOov4

72 enrolled

Ovarian Neoplasms

NCT03430700 2023-01-30

PROMPT

28 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02440425 2022-10-07

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

42 enrolled 14 charts

Carcinoma, Ovarian Neoplasms, Recurrence

NCT02865811 2022-09-13

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

26 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03029598 2022-07-26

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Completed

29 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02499952 2022-07-11

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Phase 2 Terminated

12 enrolled 14 charts

GenitourinaryGynecologic

Nonseminomatous germ cell tumor, Genital Neoplasms, Female, Genital Neoplasms, Male, Mediastinal Neoplasms, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Testicular Neoplasms

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

35 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02608684 2022-03-23

PemCiGem

21 enrolled 16 charts

Ovarian Neoplasms

NCT04375956 2021-12-20

MITO 27

100 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02853318 2021-10-06

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

40 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03539328 2018-05-29

MITO27

138 enrolled